Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On June 18, 2009 Senomyx, Inc. announced the unexpected death of Mark J. Zoller, Ph.D., our Executive Vice President of Discovery & Development and Chief Scientific Officer.

On June 30, 2009, in recognition of Dr. Zoller's past service since March 2000 and significant scientific, strategic and commercial contributions to Senomyx throughout that period, the Compensation Committee of our Board of Directors approved the acceleration of vesting of options to purchase an aggregate of 139,704 shares of our common stock, which represent the unvested portion of stock option awards granted to Dr. Zoller on January 19, 2005, February 1, 2006, February 15, 2007 and February 15, 2008 under the Senomyx 2004 Equity Incentive Plan ("the Plan"). The accelerated stock options have exercise prices ranging from $7.49 to $16.25 per share. In accordance with the Plan, Dr. Zoller's estate will have up to eighteen months following his death to exercise the options.

---